-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Tinostamustine in Peritoneal Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Tinostamustine in Peritoneal Cancer Drug Details: Tinostamustine (NL-101) is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Paclitaxel in Breast Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Paclitaxel in Breast Cancer Drug Details: Paclitaxel (FID-007) is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Atezolizumab in Breast Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Atezolizumab in Breast Cancer Drug Details: Atezolizumab (Tecentriq) is an antineoplastic agent. It is formulated...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Tislelizumab in Cervical Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Tislelizumab in Cervical Cancer Drug Details: Tislelizumab (Baizean, Tevimbra) is a humanized monoclonal antibody that...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Tislelizumab in Bladder Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Tislelizumab in Bladder Cancer Drug Details: Tislelizumab (Baizean, Tevimbra) is a humanized monoclonal antibody that...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Tislelizumab in Gallbladder Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Tislelizumab in Gallbladder Cancer Drug Details: Tislelizumab (Baizean, Tevimbra) is a humanized monoclonal antibody that...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Evorpacept in Gastric Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Evorpacept in Gastric Cancer Drug Details: evorpacept is under development for the treatment of advanced...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Opaganib in Colorectal Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Opaganib in Colorectal Cancer Drug Details: Opaganib (ABC-294640) is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Opaganib in Pancreatic Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Opaganib in Pancreatic Cancer Drug Details: Opaganib (ABC-294640) is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Nesuparib in Peritoneal Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Nesuparib in Peritoneal Cancer Drug Details: JPI-547 (NOV-1402) is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – StemVacs in Breast Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. StemVacs in Breast Cancer Drug Details: StemVacs is under development for the treatment of breast...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Ezabenlimab in Colorectal Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Ezabenlimab in Colorectal Cancer Drug Details: Ezabenlimab (BI-754091) is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Brigimadlin in Bladder Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Brigimadlin in Bladder Cancer Drug Details: Brigimadlin (BI-907828) is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Brigimadlin in Gallbladder Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Brigimadlin in Gallbladder Cancer Drug Details: Brigimadlin (BI-907828) is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Oncolytic Virus For Human Papillomavirus Associated Cancer, Human Papillomavirus Infections And Coronavirus Disease 2019 (COVID-19) in Cervical Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Oncolytic Virus For Human Papillomavirus Associated Cancer, Human Papillomavirus Infections And Coronavirus Disease 2019 (COVID-19)...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Nitroxoline in Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Nitroxoline in Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) Drug Details: Nitroxoline is...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Elenagen in Kidney Cancer (Renal Cell Cancer)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Elenagen in Kidney Cancer (Renal Cell Cancer) Drug Details: Elenagen is under development for the...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Avutometinib Potassium in Cervical Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Avutometinib Potassium in Cervical Cancer Drug Details: Avutometinib potassium (RG-7304, RO5126766) is under development for...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Felezonexor in Urinary Tract Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Felezonexor in Urinary Tract Cancer Drug Details: Felezonexor (CBS-9106) was under development for the treatment...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.